Table 1 Patients and disease characteristics
Patient characteristics | HLA 10/10 | HLA 9/10 | HLA 8/10 | p value |
|---|---|---|---|---|
Number of patients | 2567 | 723 | 108 | |
Recipient age at SCT (years, range) | 61 (50–78) | 61 (50–77) | 60 (50–73) | 0.584 |
Recipient gender, n (%) | 0.707 | |||
Male | 1386 (54 %) | 387 (53.7 %) | 62 (58 %) | |
Female | 1177 (46 %) | 334 (46.3 %) | 45 (42 %) | |
Year of SCT (median), year (%) | 2011 (00–13) | 2011 (02–13) | 2009 (00–13) | 0.001 |
Interval from diagnosis to SCT (days) | 212 | 250 | 295 | 0.0001 |
Median follow-upa (months, range) | 24 (1–150) | 24 (1–139) | 34 (3–117) | 0.042 |
Donor age (years, range) | 33 (16–61) | 36 (20–61) | 35 (20–55) | 0.02 |
Donor gender, n (%) | <10−4 | |||
Male | 1845 (73 %) | 463 (65.2 %) | 69 (64.5 %) | |
Female | 682 (27 %) | 247 (34.8 %) | 38 (35.5 %) | |
Female donor to male recipient, n (%) | 281 (11.1 %) | 106 (15 % ) | 17 (16 % ) | 0.01 |
Diagnosis, n (%) | 0.001 | |||
De novo AML | 1805 (70.3 %) | 527 (72.9 %) | 60 (55.6 %) | |
Secondary AML | 762 (29.7 %) | 196 (27.1 %) | 48 (44.4 %) | |
Cytogenetics in de novo AML, n (% of available data) | 0.235 | |||
Good | 75 (9.2 %) | 15 (5.9 %) | 2 (7.1 %) | |
Intermediate | 545 (67.2 %) | 183 (72 %) | 23 (82 %) | |
Poor | 191 (23.5 %) | 56 (22 %) | 3 (10.7 %) | |
Not available/failed | 994 (55 %) | 273 (51.8 %) | 32 (53.3 %) | |
Disease status at SCT, n (%) | 0.0002 | |||
CR1 | 1413 (55 %) | 333 (46.1 %) | 48 (44.4 %) | |
≥CR2 | 504 (19.7 %) | 171 (23.6 %) | 25 (23.2 %) | |
Active disease | 650 (25.3 %) | 219 (30.3 %) | 35 (32.4 %) | |
Source of SC, n (%) | 0.173 | |||
BM | 154 (6 %) | 56 (7.8 %) | 9 (8.3 %) | |
PB | 2413 (94 %) | 667 (92.2 %) | 99 (91.7 %) | |
Conditioning, n (%) | 0.02 | |||
Chemo alone | 1836 (71.5 %) | 550 (76.1 %) | 84 (77.8 %) | |
Low TBI | 731 (28.5 %) | 173 (23.9 %) | 24 (22.2 %) | |
In vivo T cell depletion, n (%) | <10−4 | |||
No | 672 (26.4 %) | 121 (16.9 %) | 15 (14.0 %) | |
ATG | 1460 (57.5 %) | 468 (65.2 %) | 59 (55.1 %) | |
Campath | 409 (16.1 %) | 129 (18.0 %) | 33 (30.8 %) | |
Post-transplant GVHD prophylaxis | 0.07 | |||
CsA | 504 (19.9 %) | 135 (18.8 %) | 27 (25.5 %) | |
CsA/FK 506 + MTX | 517 (20.4 %) | 177 (24.7 %) | 16 (15.1 %) | |
CsA/FK 506 + MMF | 1353 (53.4 %) | 353 (49.2 %) | 53 (50 %) | |
Other | 160 (6.3 %) | 53 (7.4 %) | 10 (9.4 %) | |
Missing | 33 | 5 | 2 | |
Karnosky at SCT, n (%) | 0.47 | |||
≤80 % | 173 (6.7 %) | 42 (5.8 %) | 9 (8.4 %) | |
>80 % | 2231 (86.9 %) | 641 (88.7 %) | 91 (84.2 %) | |
Missing | 163 (6.4 %) | 40 (5.5 %) | 8 (7.4 %) | |
Patient positive CMV serology, n (%) | 1634 (64.9 %) | 492 (69.1 %) | 67 (63.8 %) | 0.10 |
CMV risk, n (%) | 0.029 | |||
Low | 695 (27.8 %) | 155 (21.9 %) | 26 (24.8 %) | |
Intermediate | 1072 (42.8 %) | 316 (44.7 %) | 47 (44.8 %) | |
High | 734 (29.4 % ) | 236 (33.4 %) | 32 (30.5 %) | |